New hope for aHUS patients: Long-Term iptacopan study launches
NCT ID NCT05795140
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the long-term safety and effectiveness of the drug iptacopan in people with a rare blood disorder called atypical hemolytic uremic syndrome (aHUS). Participants must have completed a previous iptacopan study and still benefit from the drug. The goal is to monitor side effects and see if the drug continues to control the disease over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC UREMIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGSão Paulo, São Paulo, 05403 000, Brazil
-
Novartis Investigative Site
RECRUITINGRio de Janeiro, 22270-060, Brazil
-
Novartis Investigative Site
RECRUITINGBeijing, 100034, China
-
Novartis Investigative Site
RECRUITINGOstrava, Poruba, 708 52, Czechia
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGNagpur, Maharashtra, 440015, India
-
Novartis Investigative Site
RECRUITINGPune, Maharashtra, 411011, India
-
Novartis Investigative Site
RECRUITINGIruma-gun, Saitama, 3500495, Japan
-
Novartis Investigative Site
RECRUITINGAnkara, Yenimahalle, 06500, Turkey (Türkiye)
-
Novartis Investigative Site
RECRUITINGMersin, Yenisehir, 33110, Turkey (Türkiye)